Drug Safety

, Volume 29, Issue 10, pp 1068–1068 | Cite as

ABSTRACTS: ISoP Annual Conference ‘Joining Forces for Managing Risks’ Liège, Belgium 11–13 October, 2006

  • M. C. H. de Groot
  • E. P. van Puijenbroek
  • A. C. van Grootheest
Abstracts
  • 12 Downloads

Keywords

Lidocaine Halothane Fluconazole Ventricular Tachycardia Sevoflurane 

References

  1. 1.
    Dutch SPC Sevorane®. (version date 24-5-2005) http://www.cbg-meb.nl/IBteksten/18395.pdfGoogle Scholar
  2. 2.
    van Tuijl I, van Vught AJ. Kamertachycardie bij uitleiding uit anesthesie door medicamenteus geïnduceerd verlengd QT-interval. Tijdschr Kindergeneeskd 2003; 71(6): 246–8Google Scholar
  3. 3.
    Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991; 72(2): 137–44PubMedCrossRefGoogle Scholar
  4. 4.
    Abe K, Takada K, Yoshiya I. Intraoperative torsade de pointes ventricular tachycardia and ventricular fibrillation during sevoflurane anesthesia. Anesth Analg 1998; 86(4): 701–2PubMedGoogle Scholar
  5. 5.
    Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000; 17(11): 662–4PubMedGoogle Scholar
  6. 6.
    Park WK, Pancrazio JJ, Suh CK, et al. Myocardial depressant effects of sevoflurane. Mechanical and electrophysiologic actions in vitro. Anesthesiology 1996; 84(5): 1166–76PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • M. C. H. de Groot
    • 1
  • E. P. van Puijenbroek
    • 1
  • A. C. van Grootheest
    • 1
  1. 1.Netherlands Pharmacovigilance Centre Lareb’S-Hertogenboschthe Netherlands

Personalised recommendations